Loading...
Market
Story
Roche Halts SKYSCRAPER-06 Lung Cancer Drug Trial After Failing to Show Benefit
Jul 4, 2024, 08:03 AM
Roche has announced the termination of its Phase II/III SKYSCRAPER-06 clinical trial for metastatic non-squamous non-small cell lung cancer. The trial, which combined the PD-L1 inhibitor atezolizumab with the TIGIT inhibitor tiragolumab and chemotherapy, failed to demonstrate a significant benefit in overall survival (OS) and progression-free survival (PFS) compared to the control group. The hazard ratios for OS and PFS were 1.33 and 1.27, respectively, with 95% confidence intervals. This decision marks a significant setback for Roche's lung cancer immunotherapy efforts, particularly in comparison to established treatments like Merck's Keytruda. The trial was conducted under the ticker $RHHBY.
View original story
Similar markets
Yes • 50%
No • 50%
Roche (RHHBY) performs the best • 25%
Novo Nordisk performs the best • 25%
Eli Lilly performs the best • 25%
All perform similarly • 25%
Novartis outperforms competitors • 25%
Novartis performs equally as competitors • 25%
Novartis underperforms competitors • 25%
Stock performance is inconclusive • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
Decrease or no change • 25%
Outperforms all • 25%
Outperforms some • 25%
Matches performance • 25%
Underperforms all • 25%
Outperform • 25%
Underperform • 25%
Match performance • 25%
Significantly underperform • 25%
1st • 25%
2nd • 25%
3rd • 25%
4th or lower • 25%
Increase by more than 5% • 25%
Increase by 0-5% • 25%
No significant change • 25%
Decrease • 25%